Rigel Pharmaceuticals (RIGL) Cash & Equivalents (2010 - 2026)

Rigel Pharmaceuticals' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $24.4 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 46.62% year-over-year to $24.4 million; the TTM figure through Mar 2026 stood at $24.4 million (down 46.62% YoY), while the FY2025 annual figure was $40.6 million, down 28.49% from the prior year.
• Cash & Equivalents was $24.4 million for Q1 2026 at Rigel Pharmaceuticals, down from $40.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $56.7 million in Q4 2024 to a low of $24.4 million in Q1 2026.
• Historically, Cash & Equivalents has averaged $38.6 million across 5 years, with a median of $40.3 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents sank 67.93% in 2022, then soared 79.45% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $24.5 million in 2022, then surged by 34.04% to $32.8 million in 2023, then surged by 73.08% to $56.7 million in 2024, then decreased by 28.49% to $40.6 million in 2025, then plunged by 39.84% to $24.4 million in 2026.
• The last three Cash & Equivalents figures came in at $24.4 million (Q1 2026), $40.6 million (Q4 2025), and $48.5 million (Q3 2025), per Business Quant data.